Download PDF
Pharmacopsychiatry 2017; 50(05): 169-171
DOI: 10.1055/s-0043-118483
Editorial
© Georg Thieme Verlag KG Stuttgart · New York

Editorial to Driving Ability and Psychotropic Drugs

Gerd Laux
1   Institute of Psychological Medicine, Soyen, Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany
,
Michael Bauer
2   Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital Dresden, Dresden, Germany
› Author Affiliations
Further Information

Publication History

received16 August 2017
revised16 August 2017

accepted 16 August 2017

Publication Date:
12 September 2017 (online)

Also available at
    Permissions and Reprints

Pharmacoepidemiological data show the highly frequent use of psychotropic drugs. According to the „Arzneiverordnungs-Report“ psychotropic drugs range second among the most prescribed medicines in Germany with antidepressants being the dominating class by far [1]. Modern societies demand a high grade of mobility, driving a car is vital for the functional autonomy of patients to take part in activities of daily living and are frequently obligatory for many professions. Psychiatric illness and psychopharmacological treatments may impair driving ability [2] [3] [4] [5] [6]forreview]. Therefore, road safety under psychotropic treatment is of high societal relevance, and the reason for highlighting this rarely covered field of psychopharmacology in this special issue of Pharmacopsychiatry.

 

  • References

  • 1 Schwabe U, Paffrath D. Arzneiverordnungs-Report. Heidelberg: Springer; 2016
    Google Scholar
  • 2 Brunnauer A, Laux G. Fahrtüchtigkeit und psychische Erkrankung. In: Möller HJ, Laux G, Kapfhammer HP. Hrsg Psychiatrie, Psychosomatik, Psychotherapie. Band 4. 5.Auflage Heidelberg, Berlin: Springer; 2017
    Google Scholar
  • 3 Brunnauer A, Laux G. Psychopharmaka und Fahrtüchtigkeit. In: Riederer PF, Laux G. Hrsg Grundlagen der Neuro-Psychopharmakologie. Ein Therapiehandbuch. Wien New York: Springer; 2010. p 475-482
    Google Scholar
  • 4 DRUID Driving under the influence of Drugs, Alcohol and Medicines. 6th Framework Programme. Deliverable 1.1.2b, 4.1.1 http://www.druid-project.eu/Druid/EN/deliverales-list/downloads/Deliverable_1 1 2, 4 1 1.html?nn = 613800 [Accessed 1.8.2017]
    PubMed
  • 5 Dassanayake T, Michie P, Carter G. et al. Effects of benzodiazepines, antidepressants and opioids on driving: A systemic review and meta-analysis of epidemiological and experimental evidence. Drug Saf 2011; 34: 125-156
    CrossrefPubMedGoogle Scholar
  • 6 De las Cuevas C, Ramallo Y, Sanz EJ. Psychomotor performance and fitness to drive: The influence of psychiatric disease and its pharmacological treatment. Psychiatry Res 2010; 176: 236-241
    CrossrefPubMedGoogle Scholar
  • 7 Brunnauer A, Widder B, Laux G. Grundlagen der Fahreignungsbeurteilung bei neurologischen und psychischen Erkrankungen. Nervenarzt 2014; 85: 805-810
    CrossrefPubMedGoogle Scholar
  • 8 Brunnauer A, Laux G. The effects of most commonly prescribed second generation antidepressants on driving ability: A systematic review. J Neural Transm 2013; 120: 225-232
    CrossrefPubMedGoogle Scholar
  • 9 Fahrerlaubnisverordnung- FeV (Fassung vom 16.12.2014). http://www.fahrerlaubnisrecht.de/FeV/FeV_Inhaltsverzeichnis.htm [Accessed: 10.07.2017]
    PubMed
  • 10 Gräcmann N, Albrecht M. Begutachtungsleitlinien zur Kraftfahreignung. Bundesanstalt für Straßenwesen. Berichte der Bundesanstalt für Straßenwesen. Mensch und Sicherheit. Heft M115. Bergisch Gladbach 2014
    PubMed
  • 11 Laux G, Brunnauer A. Fahrtauglichkeit bei affektiven Störungen und unter Psychopharmaka. Nervenarzt 2014; 85: 822-828
    CrossrefPubMedGoogle Scholar
  • 12 Brunnauer A, Buschert V, Fric M. et al. Driving performance and psychomotor function in depressed patients treated with agomelatine or venlafaxine. Pharmacopsychiatry 2015; 48: 65-71
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Smink BE, Egberts AC, Lusthof KJ. et al. The relationship between benzodiazepine use and traffic accidents: A systematic literature review. CNS Drugs 2010; 24: 639-653
    CrossrefPubMedGoogle Scholar
  • 14 Laar Mv, Volkerts E. Driving and benzodiazepine use. CNS Drugs 1998; 10: 383-396
    CrossrefPubMedGoogle Scholar
  • 15 Kawano N, Iwamoto K, Iidaka T. et al. Effects of mild cognitive impairment on driving performance in older drivers. J Am Geriatr Soc 2012; 60: 1379-1381
    CrossrefPubMedGoogle Scholar
  • 16 Haussmann R, Wagner T, Müller D. et al. Beurteilung der Fahrtauglichkeit bei Patienten mit MCI und demenziellen Syndromen. Nervenarzt 2017; 88: 247-253
    CrossrefPubMedGoogle Scholar
  • 17 Dubinsky R, Stein A, Lyons K. Practice parameters: Risk of driving and Alzheimer‘s disease (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000; 54: 2205-2211
    CrossrefPubMedGoogle Scholar
  • 18 Brunnauer A, Buschert C, Laux G. Demenz und Autofahren. Nervenarzt 2014; 85: 811-815
    CrossrefPubMedGoogle Scholar
  • 19 Turk K, Dugan E. Research brief: A literature review of frontotemporal dementia and driving. Am J Alzheimers Dis Other Demen 2014; 29: 404-408
    CrossrefPubMedGoogle Scholar
  • 20 Brunnauer A, Laux G, Zwick S. Driving simulator performance and psychomotor functions of patients treated with antipsychotics. Eur Arch Psychiatry Clin Neurosci 2009; 259: 483-489
    CrossrefPubMedGoogle Scholar
  • 21 Brunnauer A, Laux G, Geiger E. et al. The impact of antipsychotics on psychomotor performance with regard to car driving skills. J Clin Psychopharmacol 2004; 24: 155-160
    CrossrefPubMedGoogle Scholar
  • 22 Kagerer S, Winter C, Möller HJ. et al. Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study. Neuropsychobiology 2003; 47: 212-218
    CrossrefPubMedGoogle Scholar
  • 23 Soyka M, Winter C, Kagerer S. et al. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. J. Psychiatry Res 2005; 33: 101-108
    PubMedGoogle Scholar
  • 24 Cox DJ, Davis M, Mikami AY. et al. Long-acting methylphenidate reduces collison rates of young adult drivers with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2012; 32: 225-230
    CrossrefPubMedGoogle Scholar